Navigation Links
Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
Date:2/25/2009

payor acceptance of our products as safe and effective therapeutic products; our ability to maintain regulatory approvals to market and sell our products; our ability to enter into additional strategic licensing, collaboration or co-promotion transactions on favorable terms, if at all; adverse side effects experienced by patients taking our products; difficulties relating to clinical trials, including difficulties or delays in the completion of patient enrollment, data collection or data analysis; the results of preclinical studies and clinical trials with respect to our products under development and whether such results will be indicative of results obtained in later clinical trials; our ability to obtain, maintain and enforce patent and other intellectual property protection for our products and product candidates; and the other factors described in Cornerstone Therapeutics' Current Report on Form 8-K, as amended, filed with the Securities and Exchange Commission (the SEC) on November 5, 2008, in the section titled "Risk Factors of the Registrant" as set forth in Exhibit 99.3, and other filings that we make with the SEC. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, our actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.

In addition, the statements in this press release reflect our expectations and beliefs as of the date of this release. We anticipate that subsequent events and developments will cause our expectations and beliefs to change. However, while we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispos
'/>"/>

SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
2. BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM)
3. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
4. Synvista Therapeutics Announces Restructuring of Dividend Obligation to Preferred Stockholders and Decision to Delist from NYSE Alternext and Terminate SEC Registration of Common Stock
5. Pearl Therapeutics Secures $8 Million in Debt Financing
6. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
7. Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million
8. CV Therapeutics Board of Directors Rejects Astellas Unsolicited Proposal
9. CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results
10. Sopherion Therapeutics Secures $55 Million in Series C Funding
11. Amicus Therapeutics Announces Change to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Charlotte, NC (PRWEB) September 19, 2014 ... Certified Biobased Product Label for its Organic Cotton ... the product’s amount of renewable biobased ingredients meets or ... or intermediate materials composed in whole or in significant ... “This logo/label will allow our Organic cotton to be ...
(Date:9/19/2014)... The new , Healthcare and Life Sciences Review ... PharmaBoardroom.com for free download , looks beyond ... economy in 2009, and the austerity measures that followed, to ... times of trouble. "Despite the crisis, ... and the general conditions to invest are favorable to the ...
(Date:9/18/2014)... 2014 /PRNewswire-iReach/ -- DeepResearchReports.com adds "2014 Deep Research ... and "2014 Deep Research Report on Global and ... database. Photo - http://photos.prnewswire.com/prnh/20140918/147058 ... Global and China Acetic Acid Industry" is a ... China and Global Acetic Acid Market. ...
(Date:9/18/2014)... September 18, 2014 Texas Governor ... Sharp, Texas A&M Health Science Center CEO Brett ... of Health and Human Services (HHS), State of ... national pandemic influenza vaccine manufacturing facility in Bryan, ... anchor for the Texas A&M Biocorridor – a ...
Breaking Biology Technology:Barnhardt Manufacturing Company Earns USDA Certified Biobased Product Certification and Label for Organic Cotton 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 4Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4
... one of the rapidly growing markets in life science field. By ... to reach $2.2 billion. Major factors that continue to affect the ... and emerging technologies. , ... San Jose, CA (PRWEB) ...
... at it, the notion of harvesting energy from the sun ... ever. , Researchers at Rensselaer Polytechnic Institute have discovered and ... solar energy. By developing a new antireflective coating that boosts ... those panels to absorb the entire solar spectrum from nearly ...
... 3 Amgen (Nasdaq:,AMGN) today announced that it ... 7, 2008 at the Millennium Broadway Hotel, 145 ... a.m. Eastern Time. Participating in,the meeting will be ... Ph.D., executive vice president, Research and Development, George,Morrow, ...
Cached Biology Technology:World Gene Amplification Technologies Market to Reach $2.2 Billion by 2015, According to New Report by Global Industry Analysts, Inc. 2World Gene Amplification Technologies Market to Reach $2.2 Billion by 2015, According to New Report by Global Industry Analysts, Inc. 3Solar power game-changer: 'Near perfect' absorption of sunlight, from all angles 2Solar power game-changer: 'Near perfect' absorption of sunlight, from all angles 3Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York 2
(Date:9/18/2014)... September 18, 2014 New research into the Crimean-Congo ... a severe hemorrhagic disease in humans similar to that ... for CCHFV infection. This discovery has the potential to ... pathogen. , The research, reported in a ... and conducted by scientists at the Texas Biomedical ...
(Date:9/18/2014)... International Space Station ever starts a "frequent flyers" program, ... Recently the orbiting laboratory has hosted increasing numbers of ... from the space station in April, and another is ... experiment is planned to launch in December. , Fruit ... the world-- and in space. Model organisms can reveal ...
(Date:9/18/2014)... spoken language is unique to humans. "The genetic changes ... human evolution to make this possible are largely unknown, ... have," says Wolfgang Enard, Professor of Anthropology and Human ... molecular biological basis of language Enard has now taken ... study, undertaken in collaboration with scientists at several universities, ...
Breaking Biology News(10 mins):Research milestone in CCHF virus could help identify new treatments 2Buzzing with activity: Fruit flies orbit Earth for science 2Buzzing with activity: Fruit flies orbit Earth for science 3Buzzing with activity: Fruit flies orbit Earth for science 4Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3
... 2010 IDenta Corp.,(PINKSHEETS: IDTA) CEO Yaacov Shoham today issued a statement concerning the,BTK-Bullet hole test ... The IDenta,s BTK- Bullet Hole Testing Kit was mentioned in news articles,on the ... To see the article, click on the ... http://www.lasvegassun.com/news/2008/jul/08/gee-whiz-packed-metro-csi-tru , , ...
... July 6, 2010 A new computer data compression ... Research Institute (TGen), will allow genetic researchers and others to ... space and at lower cost. Created specifically for genomic ... use are described in a paper published today in the ...
... known as quantum dots make ideal tools for distinguishing ... and Georgia Tech scientists have demonstrated. An article ... 15 issue of Analytical Chemistry describes how ... Reed-Sternberg cells that are characteristic of Hodgkin,s lymphoma. ...
Cached Biology News:International Drug & Explosives Detection Company IDenta Corp Reports on BTK- Bullet Hole Testing Kit 2International Drug & Explosives Detection Company IDenta Corp Reports on BTK- Bullet Hole Testing Kit 3New TGen technology reduces storage needs and costs for genomic data 2New TGen technology reduces storage needs and costs for genomic data 3Multicolor quantum dots aid in cancer biopsy diagnosis 2
... Dr. P Set from different human ... More organs maybe available upon request. ... items from the whole set, and ... price. All Dr. P Set ...
... buffer and fixative results in complete ... Vivo Manual Perfusion Fixation System ... and fixative results in complete perfusion ... clean--Complete system with everything down to ...
Mouse IL-31 RA Biotinylated Affinity Purified PAb...
... plus assay system offers the ... Designed for batch-processing systems, Long ... density microplates such as 384-well ... Convenient storage conditions ( 2 ...
Biology Products: